16-06-2016 дата публикации
Номер: US20160168122A1
Принадлежит:
The purpose of the present invention is to provide a novel triazine derivative of the formula (I): 3. The triazine derivative according to claim 1 , wherein{'sup': '1', 'claim-text': 'or a pharmaceutically acceptable salt thereof.', 'Ris a hydroxymethyl group,'}4. The triazine derivative according to claim 1 , wherein Ris a substituted or unsubstituted cycloalkyl group claim 1 ,or a pharmaceutically acceptable salt thereof.5. The triazine derivative according to claim 4 , wherein Ris a cyclopropyl group claim 4 ,or a pharmaceutically acceptable salt thereof.6. The triazine derivative according to claim 1 , wherein Ris a methyl group claim 1 ,or a pharmaceutically acceptable salt thereof.7. The triazine derivative according to claim 1 , wherein Ris a hydrogen atom claim 1 ,or a pharmaceutically acceptable salt thereof.8. The triazine derivative according to claim 1 , wherein A is a nitrogen atom claim 1 ,or a pharmaceutically acceptable salt thereof.9. The triazine derivative according to claim 1 , wherein A is C—R claim 1 ,or a pharmaceutically acceptable salt thereof.12. A pharmaceutical composition comprising the triazine derivative according to claim 1 , or a pharmaceutically acceptable salt thereof.13. A method of inhibiting a Bruton's tyrosine kinase activity in a cell claim 1 , comprising administering to the cell the triazine derivative according to claim 1 , or a pharmaceutically acceptable salt thereof.14. A method of treating a disease related to an abnormal cell response through a Bruton's tyrosine kinase in a subject in need thereof claim 12 , comprising administering to the subject the pharmaceutical composition of .15. The method of claim 14 , wherein the disease is selected from the group consisting of self-immune diseases claim 14 , inflammatory diseases claim 14 , bone diseases claim 14 , cancer claim 14 , lymphoma claim 14 , and arthritis.16. A pharmaceutical composition comprising the compound according to claim 10 , or a pharmaceutically ...
Подробнее